학술논문

Cancer-associated TERT promoter mutations abrogate telomerase silencing
Document Type
article
Source
eLife. 4(JULY 2015)
Subject
Stem Cell Research - Embryonic - Human
Genetics
Stem Cell Research
Stem Cell Research - Nonembryonic - Non-Human
Stem Cell Research - Nonembryonic - Human
Rare Diseases
Cancer
2.1 Biological and endogenous factors
Aetiology
Cell Differentiation
Cell Proliferation
Cells
Cultured
Humans
Mutation
Pluripotent Stem Cells
Promoter Regions
Genetic
Telomerase
CRISPR/CRISPR-associated systems 9 CAS9
cancer mechanism
chromosomes
developmental biology
genes
genome editing
human
immortalization
stem cells
telomerase TERT
tumor spectrum
Biochemistry and Cell Biology
Language
Abstract
Mutations in the human telomerase reverse transcriptase (TERT) promoter are the most frequent non-coding mutations in cancer, but their molecular mechanism in tumorigenesis has not been established. We used genome editing of human pluripotent stem cells with physiological telomerase expression to elucidate the mechanism by which these mutations contribute to human disease. Surprisingly, telomerase-expressing embryonic stem cells engineered to carry any of the three most frequent TERT promoter mutations showed only a modest increase in TERT transcription with no impact on telomerase activity. However, upon differentiation into somatic cells, which normally silence telomerase, cells with TERT promoter mutations failed to silence TERT expression, resulting in increased telomerase activity and aberrantly long telomeres. Thus, TERT promoter mutations are sufficient to overcome the proliferative barrier imposed by telomere shortening without additional tumor-selected mutations. These data establish that TERT promoter mutations can promote immortalization and tumorigenesis of incipient cancer cells.